Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07471048

A Decentralized, Randomized Interventional Study to Evaluate the Impact of an Over-the-Counter Magnolia Officinalis Oral Supplement on Blood Biomarkers of Immune Activation in Subjects With Psoriasis

Led by Sirt3 LLC · Updated on 2026-03-13

100

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

Sponsors

S

Sirt3 LLC

Lead Sponsor

P

People Science, Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are investigating whether Viv, a consumer-grade dietary supplement made from Magnolia officinalis bark extract, affects immune activity markers in adults with psoriasis. This clinical trial compares Viv to a placebo to understand its impact on inflammation-related proteins. Participants have stable psoriasis confirmed by a dermatologist and may have related conditions like psoriatic arthritis if not requiring systemic treatments. Participants will be randomly assigned to take either Viv, containing 200 mg of Magnolia officinalis bark extract, or a placebo daily for three months. The study is triple-blinded, meaning neither the participants nor researchers know who receives which treatment. Participants will use the supplement at home and collect blood samples themselves at the start, after one month, and after three months using provided kits. During the study, participants will complete electronic questionnaires about their psoriasis symptoms and quality of life at the beginning, one month, and three months. Researchers will analyze blood samples to measure changes in inflammatory proteins and immune cells over time. The primary outcome is the change in plasma Beta defensin 2 levels after 12 weeks. The total study period for participants is three months, with ongoing safety and adherence monitored remotely.

CONDITIONS

Brief Title

A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female aged 18 years or older at time of consent
  • Diagnosis of stable psoriasis confirmed by a dermatologist for at least 6 months
  • Patients with psoriasis-associated comorbidities including psoriatic arthritis permitted if not requiring systemic therapies
  • Able to read and understand English
  • Able to provide informed consent
  • Able to use a personal smartphone and download the Chloe app
  • Able to receive shipment of the study product within the United States
  • Willing and able to adhere to the study protocol including blood sample collection and shipping
Not Eligible

You will not qualify if you...

  • No access to a personal smartphone or unwilling to download the Chloe app
  • Use of systemic non-biologic immunosuppressive agents within 8 weeks prior to randomization
  • Use of systemic biologic therapies within 6 months prior to randomization
  • Use of other systemic investigational drugs within 6 months prior to randomization
  • Currently pregnant, planning to become pregnant in next 3 months, or breastfeeding
  • Medical conditions that may affect digestive symptom assessment or study outcomes
  • Significant illness or condition that may impact study participation or outcomes
  • Known allergy or hypersensitivity to magnolia, rice, or hypromellose
  • Unlikely to comply with study requirements or deemed unsuitable by the principal investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (remote or in-person) to confirm eligibility and consent

Treatment

Duration - 12 weeks

Participants take either a dietary supplement containing Magnolia officinalis bark extract or a placebo daily.

Weekly remote check-ins with blood sample collection and symptom reporting

Trial Site Locations

Total: 1 location

1

Decentralized Study Coordinating Center

Englewood, New Jersey, United States, 07631

Actively Recruiting

Loading map...

Research Team

A

Adeeb Rahman, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here